A recent report published by
Infinium Global Research on stool secretory immunoglobulin a [SIgA] market
provides in-depth analysis of segments and sub-segments in the global as well
as regional stool secretory immunoglobulin a [SIgA] market. The study also
highlights the impact of drivers, restraints, and macro indicators on the
global and regional stool secretory immunoglobulin a [SIgA] market over the
short term as well as long term. The report is a comprehensive presentation of
trends, forecast, and dollar values of global stool secretory immunoglobulin a
[SIgA] market. According to the report, the global stool secretory
immunoglobulin a [SIgA] market is projected to grow at a healthy CAGR over the
forecast period of 2021-2027.
The secretion of the immunoglobulin
a (IgA) antibody is one of the primary defense mechanisms protecting against
enteric infections in both human and animal models. It further provides
protective effects by binding to microbial antigens, toxins, and food proteins.
The coronavirus disease (COVID-19) causes all the healthcare R&D activities
to remain steady. Research and development activities are likely to continue
in, as governments in all the nations have given a large preference to research
and development activities pertaining to the healthcare sector. As the primary
focus of governments around the globe is on curbing the transmission of the
novel COVID-19 infection. Hence the growth of the stool secretory
immunoglobulin a (SIgA) market is anticipated to remain steady during the
COVID-19 pandemic.
Secretory immunoglobulin a (SIgA)
is the dominant immunoglobulin in external secretions that bathe mucosal
surfaces and is a vital component of the immune system against pathogenic
microorganisms, viruses, and bacteria. SIgA production is both beneficially and
adversely affected by a number of diverse factors including stress, emotions
such as frustration and anger, nutrients, commensals, pathogens, and
inflammation. A reduced mucosal barrier function may increase the risk for
allergy development and immunoglobulin A (IgA) is the primary mediator of
humoral mucosal immunity. Immunoglobulin A is the most abundantly produced
antibody in humans, with the highest amount of secretion in the intestinal
tract Secretory IgA (SIgA), has a crucial role in the gut through its binding
to bacterial antigens, thus preventing their direct interaction with the host
via immune exclusion and maintaining the mucosal homeostasis. Growing adoption
of diagnosis of selective IgA deficiency in suspected cases due to chronic or
recurrent infections, autoimmune diseases, chronic diarrhea, and benefits
offered by secretory immunoglobulin A (SIgA) diagnostics are expected to boosts
the market growth. Furthermore, a notable rise in the adoption of preventive
care for a healthier lifestyle is fuelling the market growth of stool secretory
immunoglobulin a (SIgA) during the assessment period. However, imposing pricing
pressure on major manufacturers is intensifying competition in the market. A local
player offering a wide range of reagents portfolios at lower rates is hampering
the geographic expansion of major players. Moreover, advancements in stool
secretory immunoglobulin a (SIgA) continue to highlight the interaction between
the host and microbiome which, provides a significant growth opportunity for
the market.
North America dominates the
secretory immunoglobulin a (SIgA) market. An increase in recurrent respiratory
tract infections, gastric infections, and the growing occurrence of autoimmune
diseases in North America is projected to provide a growing demand for the
secretory immunoglobulin a (SIgA) diagnostics market. A large stool secretory
immunoglobulin tests are performed by standalone and hospital-based diagnostic
laboratories in the U.S. Furthermore, the presence of major standalone
laboratories, such as Laboratory Corporation of America Holdings (LabCorp)
testing a higher volume of the patient population in the U.S. and Germany. The
higher rate of adoption of new tests and instruments by diagnostic laboratories
for secretory immunoglobulin diagnosis are key factors likely to drive the
demand for stool secretory immunoglobulin A in the labs and diagnostic centers
segment. The use of probiotics is increasing rapidly despite questionable
evidence of efficacy, particularly as it relates to pediatric acute
gastroenteritis (AGE). However, the interest in probiotics is founded on how
they may contribute to immune homeostasis by altering the microbial balance,
interacting with the host immune system, regulating inflammatory cytokines, and
increasing SIgA production.
The report on global stool
secretory immunoglobulin a [SIgA] market covers segments such as types, and
applications. On the basis of types, the sub-markets include allergic disease,
infection, GI inflammation, and autoimmune disease. On the basis of
applications, the sub-markets include hospitals, labs and diagnostic centers,
and others.
The report provides profiles of
the companies in the market such as BioVendor Group, Sigma Diagnostics Inc,
Calbiotech, Inc, Eagle Biosciences, American Laboratory Products Company,
R-Biopharm AG, Tecan Trading AG, and Others.
The report provides deep insights
into the demand forecasts, market trends, and micro and macro indicators. In
addition, this report provides insights into the factors that are driving and
restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis
given in the report brings an insight into the investment areas that existing
or new market players can consider. The report provides insights into the
market using analytical tools such as Porter's five forces analysis and DRO
analysis of stool secretory immunoglobulin a [SIgA] market. Moreover, the study
highlights current market trends and provides forecast from 2021-2027. We also
have highlighted future trends in the market that will affect the demand during
the forecast period. Moreover, the competitive analysis given in each regional
market brings an insight into the market share of the leading players.
Please Choose One of them.